30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development

Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

(2016) Hermann Haller et al.   CURRENT HYPERTENSION REPORTS

Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences

(2016) Jun Yang et al.   CURRENT OPINION IN PHARMACOLOGY

Finerenone in heart failure: walking a fine line

(2016) Matthias Naegele et al.   EUROPEAN HEART JOURNAL

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

(2016) Gerasimos Filippatos et al.   EUROPEAN HEART JOURNAL

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy

(2016) Jana Grune et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Third-generation Mineralocorticoid Receptor Antagonists

(2016) Elise P. Gomez-Sanchez   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone

(2016) L.M. Ruilope et al.   Journal of the American Society of Hypertension

Nonsteroidal antagonists of the mineralocorticoid receptor

(2015) Peter Kolkhof et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

(2015) Peter Bramlage et al.   EUROPEAN JOURNAL OF HEART FAILURE

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

(2015) Licette CY Liu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1

(2015) Larbi Amazit et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?

(2013) Johann Bauersachs   EUROPEAN HEART JOURNAL

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

(2012) Lars Bärfacker et al.   ChemMedChem

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease

(2012) Bertram Pitt et al.   EUROPEAN JOURNAL OF HEART FAILURE

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

(2011) Hari K Parthasarathy et al.   JOURNAL OF HYPERTENSION

Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics

(2011) Peter Kolkhof et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule

(2010) Jérôme Fagart et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists

(2010) Graciela B. Arhancet et al.   JOURNAL OF MEDICINAL CHEMISTRY

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stroke Therapy: Is Spironolactone the Holy Grail?

(2008) Anne M. Dorrance   ENDOCRINOLOGY

Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?

(2008) Andrew S Bomback et al.   Nature clinical practice. Nephrology